C5AR1 and neoplasm: In addition, the administration of PD-1/PD-L1 antibodies enabled the hyperactivation of the C5a-C5aR pathway, PD-1/PD-L1 antibodies combined with C5aR blockade therapy could achieve a satisfactory anti-tumor effect [33].